Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Non-Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Non-Current Assets for 16 consecutive years, with $45000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 40.62% to $45000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $45000.0, a 40.62% increase, with the full-year FY2024 number at $12000.0, down 62.5% from a year prior.
  • Other Non-Current Assets was $45000.0 for Q3 2025 at Plus Therapeutics, roughly flat from $45000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $45000.0 in Q2 2025 to a low of $12000.0 in Q3 2022.
  • A 5-year average of $22722.2 and a median of $16000.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 166.67% in 2023, then plummeted 62.5% in 2024.
  • Plus Therapeutics' Other Non-Current Assets stood at $16000.0 in 2021, then dropped by 25.0% to $12000.0 in 2022, then surged by 166.67% to $32000.0 in 2023, then tumbled by 62.5% to $12000.0 in 2024, then surged by 275.0% to $45000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Other Non-Current Assets are $45000.0 (Q3 2025), $45000.0 (Q2 2025), and $19000.0 (Q1 2025).